NCT01129531View on ClinicalTrials.gov

A Study of the Safety and Efficacy of AGN-214868 in Patients With Postherpetic Neuralgia

PHASE2CompletedINTERVENTIONAL
Enrollment

294

Participants

Timeline

Start Date

June 30, 2010

Primary Completion Date

October 31, 2011

Study Completion Date

January 31, 2012

Conditions
Neuralgia, Postherpetic
Interventions
DRUG

AGN-214868

AGN-214868 injected into areas of postherpetic neuralgia pain for total dose per treatment.

DRUG

Placebo to AGN-214868

Placebo to AGN-214868 injected into areas of postherpetic neuralgia pain per treatment.

Trial Locations (4)

Unknown

Orlando

Brno

Kiel

Katowice

Sponsors

Lead Sponsor

Allergan
All Listed Sponsors
lead

Allergan

INDUSTRY